Skip to content
10-Q

Quarterly Report

Satsuma Pharmaceuticals, Inc.

0000950170-23-021208

← back to feed
Filed
May 11, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 8, 2023 33.15M sh
Shares Diluted Q1 2023 · Mar 31, 2023 33.15M sh
Shares Diluted Q1 2023 · Mar 31, 2022 31.55M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$11.39M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$14.32M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $19.53M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $16.43M
Stockholders Equity Q1 2023 · Mar 31, 2023 $37.65M
Stockholders Equity Q1 2023 · Dec 31, 2022 $46.82M
Stockholders Equity Q1 2023 · Mar 31, 2022 $86.98M
Stockholders Equity Q1 2023 · Dec 31, 2021 $101.34M
Current Liabilities Q1 2023 · Mar 31, 2023 $5.83M
Current Liabilities Q1 2023 · Dec 31, 2022 $8.12M
Total Liabilities Q1 2023 · Mar 31, 2023 $5.83M
Total Liabilities Q1 2023 · Dec 31, 2022 $8.12M
Current Assets Q1 2023 · Mar 31, 2023 $43.38M
Current Assets Q1 2023 · Dec 31, 2022 $54.81M
Total Assets Q1 2023 · Mar 31, 2023 $43.48M
Total Assets Q1 2023 · Dec 31, 2022 $54.94M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.31
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.49
Eps Basic Q1 2023 · Mar 31, 2023 −$0.31
Eps Basic Q1 2023 · Mar 31, 2022 −$0.49
Sga Expense Q1 2023 · Mar 31, 2023 $3.31M
Sga Expense Q1 2023 · Mar 31, 2022 $3.99M
Rd Expense Q1 2023 · Mar 31, 2023 $7.46M
Rd Expense Q1 2023 · Mar 31, 2022 $11.56M
Net Income Q1 2023 · Mar 31, 2023 −$10.29M
Net Income Q1 2023 · Mar 31, 2022 −$15.52M
Operating Income Q1 2023 · Mar 31, 2023 −$10.77M
Operating Income Q1 2023 · Mar 31, 2022 −$15.55M
Capex Q1 2023 · Mar 31, 2022 $24K